Document Detail

Comparison of kaolin and tissue factor activated thromboelastography in haemophilia.
MedLine Citation:
PMID:  20028419     Owner:  NLM     Status:  MEDLINE    
A limitation of bypassing agent therapy for haemophilia patients with inhibitors is the absence of a laboratory assay, which predicts the clinical response to treatment. Recent investigations have demonstrated the potential for thromboelastography to assess the effects of bypassing agent therapy in this patient population. While tissue factor activation has been used in several prior studies, a recent multicentre study failed to demonstrate an expected concentration-response effect of rFVIIa and called into question the tissue factor activation methods that have been employed. A comparison of kaolin to two concentrations of tissue factor as the activation method for thromboelastography was investigated in patients with haemophilia. We performed kaolin and tissue factor activated thromboelastography on blood from inhibitor and non-inhibitor patients with and without addition of rFVIIa and rFVIII. The results demonstrate that kaolin leads to a longer R, K and angle than the higher dilution of tissue factor (1:17 000) at baseline (no factor) and after addition of rFVIIa for both the inhibitor and non-inhibitor patients. Kaolin led to a longer R and K in comparison to a low dilution of tissue factor (1:42 000) following the addition of rFVIIa in the inhibitor patients. The longer R and K allows for better discrimination of the effects of rFVIIa thus making kaolin the most sensitive activation method in this setting. Thus kaolin activated thromboelastography should be considered an effective, perhaps the most effective, activator when utilizing thromboelastography to assess the effects of rFVIIa in haemophilia patients with inhibitors.
G Young; R Zhang; R Miller; D Yassin; D J Nugent
Related Documents :
21288959 - Remission is the goal for cardiovascular risk management in patients with rheumatoid ar...
16787769 - Prophylactic and therapeutic use of recombinant activated factor vii in patients with c...
10555699 - Manifestations of factor viii inhibitor in the head and neck.
11697019 - Correlation between self-reported adherence to highly active antiretroviral therapy (ha...
19350119 - Microparticle-linked tissue factor activity and increased thrombin activity play a pote...
21236309 - Evidence of neutrophil functional defect despite inflammation in stable cirrhosis.
14767719 - Decreased cerebrospinal fluid cgmp levels in patients with amyotrophic lateral sclerosis.
15236659 - Risk factors and in-hospital outcomes in stroke and myocardial infarction patients.
9259429 - Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter ou...
Publication Detail:
Type:  Journal Article     Date:  2009-12-17
Journal Detail:
Title:  Haemophilia : the official journal of the World Federation of Hemophilia     Volume:  16     ISSN:  1365-2516     ISO Abbreviation:  Haemophilia     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-06-11     Completed Date:  2010-09-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9442916     Medline TA:  Haemophilia     Country:  England    
Other Details:
Languages:  eng     Pagination:  518-24     Citation Subset:  IM    
Division of Hematology/Oncology, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Coagulation / drug effects
Drug Interactions
Factor VIII / pharmacology*
Factor VIIa / pharmacology*
Hemophilia A / blood,  drug therapy*
Kaolin / pharmacology*,  therapeutic use
Recombinant Proteins / pharmacology
Thrombelastography / methods*
Young Adult
Reg. No./Substance:
0/Recombinant Proteins; 0/recombinant FVIIa; 1332-58-7/Kaolin; 9001-27-8/Factor VIII; EC VIIa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melp...
Next Document:  Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.